Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cefadroxil · 2 trials · 1 indication
Bioequivalence based on Cmax.
Bioequivalence based on AUC0-t.
Bioequivalence based on AUC0-inf.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Cefadroxil 500 mg Capsules | DRUG | 1 x 500 mg |
| DURICEF® capsules 500 mg | DRUG | 1 x 500 mg |
Inclusion Criteria: * Non-smoking male or female with a minimum age of 18 years (i.e. non-smoker or non-tobacco user for at least 90 days prior to pre-study medical screening. * Body mass index (BMI= weight/height2 greater than or equal to 19kg/m2 and less than or equal to 30kg/m2. * Availability o...
Cefadroxil is a small molecule drug developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. It has been studied in Phase 1 clinical trials involving healthy adult volunteers. The specific therapeutic indications for this asset are undisclosed.
Cefadroxil is made by Teva Pharmaceutical Industries Limited, a company listed on the stock exchange under the ticker symbol TEVA. Teva is responsible for the development and clinical evaluation of this small molecule asset.
Cefadroxil is in Phase 1 clinical development. Two Phase 1 trials have been completed, and there are currently no active trials. The total enrollment across these completed studies was 52 participants.
Cefadroxil has been evaluated in two completed Phase 1 trials: NCT00835081, titled Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects, and NCT00834275, titled Cefadroxil 500 mg Capsules Under Fasting Conditions. Both enrolled 26 participants in the United States and Canada.